• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Will Heavily Investigate AstraZeneca Vaccine Safety Issue, Hahn Says

FDA Will Heavily Investigate AstraZeneca Vaccine Safety Issue, Hahn Says

September 21, 2020

Health regulators abroad have begun giving the OK for AstraZeneca to resume its phase 3 COVID-19 vaccine trial following a single unexplained patient illness, but the FDA has still not cleared the trial to start back up, with FDA Commissioner Stephen Hahn saying the agency will engage in “very significant work” with the company to unravel the safety issue.

Hahn said during an interview with Sen. Tim Scott (R-S.C.) that the FDA will be devoting serious effort to helping the British drugmaker conclude “if there’s a significant safety issue or not.” The agency’s concern revolves around a serious adverse event in a UK patient enrolled in AstraZeneca’s late-stage vaccine trial, the cause of which has not yet been determined.

“We don’t have all the facts, so we don’t know the causation per se of this, but we really need to look into it,” Hahn said. “What FDA does is we take our responsibilities around safety very seriously. We need to take it all seriously no matter where it occurred.”

AstraZeneca said last week that it had nothing new to share on the trial pause in the U.S. and cannot provide details on its discussions with regulators, including the FDA.

Hahn reiterated in his remarks that the agency will only approve or authorize a COVID-19 vaccine if it is found safe and effective through proper research, addressing concerns that the agency could give in to pressure from the Trump administration to deliver a vaccine before the presidential election.

The Drugs Controller General of India (DCGI) is the latest health regulator to allow research on the promising vaccine candidate to resume, giving the Serum Institute of India the go-ahead Tuesday to start its trial back up. UK, Brazilian and South African trials have also begun again.

The FDA declined to comment further on its investigation into the vaccine safety issue. The National Institutes of Health has started its own investigation, according to an agency investigator, though it’s still in the early stages. The medical research agency has expressed great concern about the situation and urged AZ to share more details about the adverse event.

COVID-19
  • Related Directories

    Veklury (remdesivir)

    Pfizer-BioNtech COVID-19 Vaccine

    Moderna COVID-19 Vaccine (mRNA-1273)

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing